Naftidrofuryl (oxalate) (Standard)

Naftidrofuryl (oxalate) (Standard) is the analytical standard of Naftidrofuryl (oxalate). This product is intended for research and analytical applications. Naftidrofuryl oxalate (Nafronyl oxalate salt) is an orally active 5-HT₂ receptor antagonist. Naftidrofuryl oxalate selectively blocks vascular and platelet 5-HT₂ receptors, inhibiting Serotonin (HY-B1473A)-induced vasoconstriction, platelet aggregation, and vascular smooth muscle cell proliferation. Naftidrofuryl oxalate can be used for the research of intermittent claudication, peripheral occlusive arterial disease, and critical limb ischaemia^[1][2][3]. IC50 & Target:5-HT2 receptor In Vitro:Naftidrofuryl oxalate (Nafronyl oxalate salt) may be effective for relieving the pain of muscle cramps^[1].
Naftidrofuryl oxalate (Nafronyl oxalate salt) is the only vasoactive drug for peripheral arterial disease (PAD) which is likely to be cost-effective^[2].
Naftidrofuryl oxalate (Nafronyl oxalate salt) is ranked first for both maximum walking distance (MWD) and pain-free walking distance (PFWD) (probability of 0·947 and 0·987, respectively, of being the best treatment) followed by cilostazol and pentoxifylline. Naftidrofuryl oxalate (Nafronyl oxalate salt) is effective treatments for claudication, Naftidrofuryl oxalate is likely to be the most effective, with minimal serious adverse events^[3].